Skip to content

US · CGEN · BIOTECHNOLOGY

Compugen Ltd. (CGEN) intrinsic value and stock valuation

$1.84as of 2026-11-21 · Mkt cap 215.58M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Compugen Ltd. DCF and intrinsic value

InvestorsCraft values CGEN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CGEN’s statements →

Compugen Ltd. Graham Number

Graham Number: $3.06d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Holon, TA 5885849 cgen.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$72.8M+105.2% 5y CAGRd
20112025
Net income
$35.3M
20112025
Free cash flow
$31.3M
20112025
Total equity
$102.7M-3% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$72.8M$27.9M$33.5M$7.5M$6M
Operating income$31.3M-$-14.89M-$-12.99M-$-35.37M-$-35.07M
Net income$35.3M-$-14.23M-$-18.75M-$-33.69M-$-34.2M
EPSd$376.7K-$-158.94K-$-213.97K-$-389.21K-$-406.18K
Operating cash flow$31.6M$49.6M-$-35.89M-$-34.51M-$-22.75M
Capital expenditure-$-310K-$-120K-$-170K-$-490K-$-290K
Free cash flow$31.3M$49.5M-$-36.06M-$-34.99M-$-23.04M
Total assets$156.9M$115M$121.3M$94.2M$132.2M
Total debt$2.96M$2.91M$1.35M$1.93M$2.75M
Net debt-$-87.64M-$-15.32M-$-12.54M-$-9.13M-$-5.05M
Total equity$102.7M$54.9M$65.6M$77.7M$106.7M
Cash and short-term investments$145.6M$103.3M$50.7M$83.4M$117.1M
Income statement
20252024202320222021
Revenue$72.8M$27.9M$33.5M$7.5M$6M
Cost of revenue$9.25M$7.93M$2M$970K$680K
Gross profit$63.5M$19.9M$31.5M$6.53M$5.32M
Research and development expenses$22.8M$24.8M$34.5M$30.7M$28.7M
Selling, general and administrative expenses$9.43M$10M$9.97M$11.3M$11.7M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$32.2M$34.8M$44.5M$41.9M$40.4M
Cost and expenses$41.4M$42.8M$46.5M$42.9M$41.1M
Interest income$4.41M$5.24M$3.24M$1.44M$890K
Interest expense$0.00$30K$30K$30K$30K
Depreciation and amortization$470K$490K$480K$480K$460K
Ebitda$35.9M-$-9.19M-$-9.28M-$-33.13M-$-33.72M
Operating income$31.3M-$-14.89M-$-12.99M-$-35.37M-$-35.07M
Total other income/expenses, net$4.07M$5.18M$3.21M$1.74M$870K
Income before tax$35.4M-$-9.71M-$-9.78M-$-33.64M-$-34.2M
Income tax expense$50K$4.52M$8.97M$60K$0.00
Net income$35.3M-$-14.23M-$-18.75M-$-33.69M-$-34.2M
Weighted average shares outstanding$93.4M$89.5M$87.6M$86.6M$84.2M
Weighted average diluted shares outstanding$93.8M$89.5M$87.6M$86.6M$84.2M
Balance sheet
20252024202320222021
Cash and short-term investments$145.6M$103.3M$50.7M$83.4M$117.1M
Net receivables$290K$270K$61.3M$320K$190K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$148M$106M$114.6M$86.1M$123.2M
Property, plant and equipment, net$3.2M$3.69M$2.54M$3.36M$3.9M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$410K$0.00$0.00$0.00$0.00
Total non-current assets$8.85M$9M$6.75M$8.05M$8.94M
Total assets$156.9M$115M$121.3M$94.2M$132.2M
Accounts payable$2.35M$1.84M$3.5M$1.77M$4.62M
Short-term debt$520K$450K$630K$610K$770K
Deferred revenue$11M$9.63M$11.2M$0.00$0.00
Total current liabilities$22.6M$20.2M$26.3M$11.9M$17.1M
Long-term debt$2.44M$2.46M$720K$1.31M$1.98M
Deferred revenue, non-current$24.9M$34.1M$25.4M$0.00$0.00
Total non-current liabilities$31.6M$39.9M$29.5M$4.58M$8.37M
Capital lease obligations$2.96M$2.91M$1.35M$1.93M$2.75M
Total liabilities$54.1M$60.1M$55.8M$16.5M$25.5M
Common stock$260K$250K$250K$240K$240K
Retained earnings-$-453.42M-$-488.76M-$-474.53M-$-455.77M-$-422.08M
Accumulated other comprehensive income (loss)$10K$10K$0.00$0.00$0.00
Total equity$102.7M$54.9M$65.6M$77.7M$106.7M
Total investments$55.5M$85M$36.8M$72.3M$109.3M
Total debt$2.96M$2.91M$1.35M$1.93M$2.75M
Net debt-$-87.64M-$-15.32M-$-12.54M-$-9.13M-$-5.05M
Cash flow statement
20252024202320222021
Net income$35.3M-$-14.23M-$-18.75M-$-33.69M-$-34.2M
Depreciation and amortization$470K$490K$480K$480K$460K
Stock-based compensation$0.00$3.02M$3.55M$4.33M$4.28M
Change in working capital-$-5.35M$62.1M-$-20.71M-$-5.55M$6.82M
Accounts receivable$360K$59.9M-$-61.11M$3.04M$2M
Inventory$0.00$0.00$0.00$0.00-$-3.37M
Accounts payable$520K-$-4.41M$3.51M-$-1.6M$3.37M
Net cash provided by operating activities$31.6M$49.6M-$-35.89M-$-33.92M-$-23.22M
Investments in property, plant and equipment-$-310K-$-120K-$-170K-$-490K-$-290K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$30M-$-46.25M$35.5M$37.1M$6.62M
Common stock issued$10.6M$540K$3.08M$350K$15M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$10.6M$550K$3.08M$350K$16.8M
Net change in cash$72.4M$3.97M$2.83M$2.91M$700K
Cash at end of period$90.6M$18.2M$14.3M$11.4M$8.51M
Operating cash flow$31.6M$49.6M-$-35.89M-$-34.51M-$-22.75M
Capital expenditure-$-310K-$-120K-$-170K-$-490K-$-290K
Free cash flow$31.3M$49.5M-$-36.06M-$-34.99M-$-23.04M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Compugen Ltd.

        Compugen Ltd., an Israeli-based company established in 1993 and headquartered in Holon, is a clinical-stage enterprise focused on the discovery, development, and commercialization of therapeutic and product candidates. Its operations extend across Israel, the United States, and Europe. The company’s core activities center around its immuno-oncology pipeline, which includes several investigational treatments: COM701, an anti-PVRIG antibody currently undergoing Phase I clinical studies for solid tumors. COM902, a therapeutic antibody designed to target TIGIT, which is also in Phase I clinical trials as a monotherapy for advanced malignancies. Bapotulimab, an antibody targeting ILDR2, presently in Phase I clinical development for solid tumor indications. AZD2936, an innovative bispecific antibody targeting both TIGIT and PD-1, advancing through Phase I/II clinical studies for patients with advanced or metastatic non-small cell lung cancer. Additionally, Compugen maintains earlier-stage immuno-oncology programs, with a particular emphasis on myeloid targets. To further its research and development, Compugen actively fosters strategic alliances. It has a collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics that modulate immune checkpoint regulators. Another key partnership is with Bristol-Myers Squibb, aimed at evaluating the safety and tolerability of COM701 when administered alongside Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo, in patients with advanced solid tumors. The company also collaborates with Johns Hopkins School of Medicine to investigate novel T cell and myeloid checkpoint targets, and has a distinct research collaboration with Johns Hopkins University specifically dedicated to myeloid science. Furthermore, Compugen holds a licensing agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products.

        CEO
        Eran Ophir
        Employees
        75
        Beta
        2.77

        Explore

        Frequently asked questions

        What is the intrinsic value of Compugen Ltd. (CGEN)?

        InvestorsCraft does not currently publish an intrinsic value for CGEN. How the IC value is calculated.

        Is CGEN undervalued?

        InvestorsCraft does not publish an undervaluation signal for CGEN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.